| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/1753-0407.12054 |
| P698 | PubMed publication ID | 23551748 |
| P2093 | author name string | Wen Xu | |
| Jianping Weng | |||
| P2860 | cites work | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 |
| Global estimates of the prevalence of diabetes for 2010 and 2030 | Q29547218 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
| Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function | Q31895027 | ||
| Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review | Q34016162 | ||
| Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials | Q34083400 | ||
| Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats | Q34103753 | ||
| Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? | Q34111683 | ||
| Islet beta cell failure in type 2 diabetes | Q34698810 | ||
| The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes | Q35085591 | ||
| Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission | Q35123342 | ||
| Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes | Q35184167 | ||
| Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion | Q35981591 | ||
| Metabolic memory in diabetes--focus on insulin | Q35993691 | ||
| beta-cell failure in diabetes and preservation by clinical treatment | Q36757992 | ||
| Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy | Q36906173 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| The islet beta-cell: fuel responsive and vulnerable | Q37262069 | ||
| Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? | Q37364945 | ||
| Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity | Q37707665 | ||
| Insulin therapy stimulates lipid synthesis and improves endocrine functions of adipocytes in dietary obese C57BL/6 mice | Q37728180 | ||
| The burden of treatment failure in type 2 diabetes | Q40500624 | ||
| LysB3, GluB29 insulin: a novel insulin analog with enhanced β-cell protective action | Q40627561 | ||
| Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells | Q41028530 | ||
| Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion | Q42435709 | ||
| Effect of short‐term intensive insulin therapy on quality of life in type 2 diabetes | Q42477142 | ||
| Basal insulin and cardiovascular and other outcomes in dysglycemia | Q42507791 | ||
| The response to short-term intensive insulin therapy in type 2 diabetes | Q43279191 | ||
| Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes | Q43867562 | ||
| Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy | Q44389355 | ||
| Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients | Q44526955 | ||
| Short-term intensive insulin therapy in newly diagnosed type 2 diabetes | Q44865579 | ||
| Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function | Q45124452 | ||
| Pancreatic beta-cell mass in European subjects with type 2 diabetes | Q46332814 | ||
| Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. | Q46576386 | ||
| Effect of a multifactorial intervention on mortality in type 2 diabetes | Q46767642 | ||
| Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients | Q46966714 | ||
| Insulin-like growth factors and pancreas beta cells | Q47759714 | ||
| Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. | Q51570046 | ||
| Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment | Q57499758 | ||
| The Importance of -Cell Failure in the Development and Progression of Type 2 Diabetes | Q58037213 | ||
| Intensive insulin therapy in patients with type 2 diabetes | Q58886203 | ||
| P433 | issue | 3 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 268-274 | |
| P577 | publication date | 2013-05-29 | |
| P1433 | published in | Journal of diabetes | Q27020371 |
| P1476 | title | Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes | |
| P478 | volume | 5 |
| Q85305515 | Early therapy for type 2 diabetes in China |
| Q38246691 | Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps |
| Q42511731 | Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9. |
| Q54985686 | Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review. |
Search more.